Corbus Pharmaceuticals Initiates Resunab™ Phase 2 Trial for the Treatment of Systemic Lupus Erythematosus
Source: Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company,announced today that Resunab™ will be tested for efficacy and safety in a Phase 2 clinical study in systemic lupus erythematosus (SLE). The SLE trial has been selected for funding by the NIH Autoimmunity Centers of Excellence (ACE) program, through a grant to the Feinstein Institute for Medical Research (FIMR), Manhasset, NY.
The Phase 2 trial will test the efficacy, safety, tolerability and biologic effects of Resunab as a novel, non-immunosuppressive oral treatment to improve signs and symptoms of SLE. The study plans to enroll 100 adult SLE patients with active musculoskeletal disease and will be carried out at approximately 10 sites in the United States. These patients will receive either placebo or three different doses of Resunab daily for 84 days with 28 days follow-up.
Meggan Mackay, M.D., M.S., Principal Investigator for the trial, said, "The musculoskeletal system is the most commonly involved system in our patients that causes significant daily pain related to inflammation. After five years of disease, joint involvement affects about 85% of SLE patients. Patients with SLE have limited options for treatment of active disease with non-immunosuppressive drugs. We look forward to testing Resunab for treatment of active musculoskeletal disease and overall disease activity in SLE."